Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
48.77
-0.43 (-0.87%)
At close: Apr 6, 2026, 4:00 PM EDT
48.61
-0.16 (-0.33%)
Pre-market: Apr 7, 2026, 4:38 AM EDT
Moderna Employees
Moderna had 4,700 employees as of December 31, 2025. The number of employees decreased by 1,100 or -18.97% compared to the previous year.
Employees
4,700
Change (1Y)
-1,100
Growth (1Y)
-18.97%
Revenue / Employee
$413,617
Profits / Employee
-$600,426
Market Cap
19.34B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4,700 | -1,100 | -18.97% |
| Dec 31, 2024 | 5,800 | 200 | 3.57% |
| Dec 31, 2023 | 5,600 | 1,700 | 43.59% |
| Dec 31, 2022 | 3,900 | 1,200 | 44.44% |
| Dec 31, 2021 | 2,700 | 1,400 | 107.69% |
| Dec 31, 2020 | 1,300 | 470 | 56.63% |
| Dec 31, 2019 | 830 | 70 | 9.21% |
| Dec 31, 2018 | 760 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Madrigal Pharmaceuticals | 915 |
| Revolution Medicines | 883 |
| BridgeBio Pharma | 839 |
MRNA News
- 11 hours ago - Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 - Accesswire
- 4 weeks ago - What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Benzinga
- 4 weeks ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 4 weeks ago - Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang - Reuters
- 4 weeks ago - Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
- 4 weeks ago - Moderna Stock Rallies. This Big Risk Just Got Eliminated. - Barrons
- 4 weeks ago - Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline - Market Watch
- 4 weeks ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ